
Global Generic Injectables Market (2022 Edition) – Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)
Description
Global Generic Injectables Market (2022 Edition) – Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)
Executive Summary
The global generic injectables market was valued at USD 134 billion in the year 2021 with the North American region leading the regional market share. Some of the key factors driving the generic injectables market growth are the expiration of branded drug patents, rising approvals for generic injectable drugs, rising aged population and the rising prevalence of life-threatening diseases among the global population. In addition, as compared to the costs of branded drugs, generic injectables are relatively inexpensive and used in the treatment of major diseases such as cancer, cardiovascular diseases, diabetes, and so on that further supports market demand.
The Asia Pacific is estimated to be the fastest-growing region due to the growing focus of Indian companies on complex generics and the rise in the adoption of generic injectables due to its cost-efficient nature. In addition, the APAC countries (China and India) have the highest prevalent cases of different chronic diseases, which is projected to fuel the market growth in upcoming years. Meanwhile, North America will remain the dominant region in the global Generic Injectables market. The United States in the North American region and China in Asia-Pacific are the major countries in the Generic Injectables market globally.
The outbreak of COVID-19 showed an impact on the global generic injectables market because hospitals, healthcare services, and drug manufacturers were significantly affected due to a variety of restrictions imposed by governments across the globe such as social distancing, travel restrictions, border closures, restrictions on public gatherings, work from home and so on. COVID-19 has had a direct impact on both supply and demand and created disruption in the supply chain, as many injectable drugs could not reach the market on time. Although the impact of COVID-19 in the pharmaceutical industry was a bit lesser compared to other industries, it still has been harmed in some ways. Many clinical trials were delayed due to the pandemic, as researchers were not permitted to visit the laboratories and continue those ongoing trials. If there were no disruptions, those molecules would come into the market as a patented molecule, hence increasing the generic injectables market in the forecast period.
Pfizer Inc. is the world's leading generic injectables company, having strengthened its position through the introduction of several generic injectable drugs as well as mergers & partnerships with regional pharma companies. Recently in 2021, Pfizer Inc. partnered with Eli Lilly and Company, an American pharmaceutical company, to announce the approval of tanezumab, a generic injectable drug for treating osteoarthritis pain in the United States. With more branded drugs coming off patent in the coming years, Pfizer has a clear plan to develop generic versions of those injectables and obtain FDA approvals to bring them to market.
Scope of the Report
Executive Summary
The global generic injectables market was valued at USD 134 billion in the year 2021 with the North American region leading the regional market share. Some of the key factors driving the generic injectables market growth are the expiration of branded drug patents, rising approvals for generic injectable drugs, rising aged population and the rising prevalence of life-threatening diseases among the global population. In addition, as compared to the costs of branded drugs, generic injectables are relatively inexpensive and used in the treatment of major diseases such as cancer, cardiovascular diseases, diabetes, and so on that further supports market demand.
The Asia Pacific is estimated to be the fastest-growing region due to the growing focus of Indian companies on complex generics and the rise in the adoption of generic injectables due to its cost-efficient nature. In addition, the APAC countries (China and India) have the highest prevalent cases of different chronic diseases, which is projected to fuel the market growth in upcoming years. Meanwhile, North America will remain the dominant region in the global Generic Injectables market. The United States in the North American region and China in Asia-Pacific are the major countries in the Generic Injectables market globally.
The outbreak of COVID-19 showed an impact on the global generic injectables market because hospitals, healthcare services, and drug manufacturers were significantly affected due to a variety of restrictions imposed by governments across the globe such as social distancing, travel restrictions, border closures, restrictions on public gatherings, work from home and so on. COVID-19 has had a direct impact on both supply and demand and created disruption in the supply chain, as many injectable drugs could not reach the market on time. Although the impact of COVID-19 in the pharmaceutical industry was a bit lesser compared to other industries, it still has been harmed in some ways. Many clinical trials were delayed due to the pandemic, as researchers were not permitted to visit the laboratories and continue those ongoing trials. If there were no disruptions, those molecules would come into the market as a patented molecule, hence increasing the generic injectables market in the forecast period.
Pfizer Inc. is the world's leading generic injectables company, having strengthened its position through the introduction of several generic injectable drugs as well as mergers & partnerships with regional pharma companies. Recently in 2021, Pfizer Inc. partnered with Eli Lilly and Company, an American pharmaceutical company, to announce the approval of tanezumab, a generic injectable drug for treating osteoarthritis pain in the United States. With more branded drugs coming off patent in the coming years, Pfizer has a clear plan to develop generic versions of those injectables and obtain FDA approvals to bring them to market.
Scope of the Report
- The report analyses the Generic Injectables Market by Value (USD Billion).
- The report presents the analysis of Generic Injectables Market for the historical period of 2017-2021 and the forecast period of 2022-2027.
- The report analyses the Generic Injectables Market by Molecule Type (Small Molecule, Large Molecule).
- The report analyses the Generic Injectables Market by Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes, Others)
- The report analyses the Generic Injectables Market by Container (Vials, Ampoules, Pre-filled Syringes and Others)
- The Global Generic Injectables Market has been analysed By Region (North America, Europe, Asia Pacific, and LAMEA).
- The Global Generic Injectables Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, Australia).
- The key insights of the report have been presented through the frameworks of SWOT Analysis. Also, the attractiveness of the market has been presented by region, by Molecule Type, by Therapeutic Area and by Container.
- Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
- The report tracks competitive developments, strategies, and a List of First-Time Generic Injectables Approvals in 2021. The companies analysed in the report include Pfizer Inc., Novartis, Sanofi, Baxter International, Fresenius SE & Co KGaA, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Gland Pharma, Teva Pharmaceuticals and Nichi-iko Pharmaceutical.
- Injectable Drug Manufacturers & Distributors
- Pharmaceutical, Biopharmaceutical & Biotechnological Companies
- End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers & Others)
- Research and Development (R&D) Organizations
- Government Bodies & Regulating Authorities
- Investment Banks and Equity Firms
Table of Contents
240 Pages
- 1. Report Scope and Methodology
- 1.1 Scope of the Report
- 1.2 Research Methodology
- 1.3 Executive Summary
- 2. Strategic Recommendations
- 3. Generic Injectables Market: Product Overview
- 4. Global Generic Injectables Market: An Analysis
- 4.1 Market Size, By Value, 2017-2027
- Table 1: Global Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- 4.2 Global Generic Injectables Market: Growth & Forecast
- 4.3 Impact of COVID-19 on Generic Injectables Market
- Table 2: Global Estimated number of Cancer incidences and prevalent cases (all ages, in millions), 2020
- Table 3: Global Cancer related number of deaths (all ages, in thousands), 2020
- Table 4: Global Estimated number of Diabetes prevalent cases (adults (20-79), in millions), 2021
- Table 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
- Table 6: Global Aged Population (Above 65), 2015-20 (% of Total Population)
- Table 7: Global Aged Population (Above 65), By Country, 2020 (% of Total Population)
- Table 8: Global Medical Spending in 2020, By Region, (% of Total)
- Table 9: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
- Table 10: Global Expected Healthcare Industry Outlook
- Table 11: Regional Expected Healthcare Industry Growth Rate, 2024
- 5. Global Generic Injectables Market Segmentation, By Molecule Type (Value)
- 5.1 Competitive Scenario of Global Generic Injectables Market: By Molecule Type
- Table 12: Global Generic Injectables Market- By Molecule Type Market Share, 2021 & 2027
- 5.2 Global Generic Injectables Market: Segment Analysis
- 5.3 By Small Molecule - Market Size and Forecast (2017-2027)
- Table 13: Global Generic Injectables Market- By Small Molecule, By Value (USD Billion), 2017-2027
- 5.4 By Large Molecule - Market Size and Forecast (2017-2027)
- Table 14: Global Generic Injectables Market- By Large Molecule, By Value (USD Billion), 2017-2027
- 6. Global Generic Injectables Market Segmentation, By Therapeutic Area (Value)
- 6.1 Competitive Scenario of Global Generic Injectables Market: By Therapeutic Area (2021 & 2027)
- Table 15: Global Generic Injectables Market - By Therapeutic Area Market Share, 2021 & 2027
- 6.2 Global Generic Injectables Market: Segment Analysis
- 6.3 By Oncology - Market Size and Forecast (2017-2027)
- Table 16: Global Generic Injectables Market- By Oncology, By Value (USD Billion), 2017-2027
- 6.4 By Anti-infectives - Market Size and Forecast (2017-2027)
- Table 17: Global Generic Injectables Market- By Anti-infectives, By Value (USD Billion), 2017-2027
- 6.5 By Cardiovascular - Market Size and Forecast (2017-2027)
- Table 18: Global Generic Injectables Market- By Cardiovascular, By Value (USD Billion), 2017-2027
- 6.6 By Diabetes - Market Size and Forecast (2017-2027)
- Table 19: Global Generic Injectables Market- By Diabetes, By Value (USD Billion), 2017-2027
- 6.7 By Others - Market Size and Forecast (2017-2027)
- Table 20: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
- 7. Global Generic Injectables Market Segmentation, By Container (Value)
- 7.1 Competitive Scenario of Global Generic Injectables Market: By Container (2021 & 2027)
- Table 21: Global Generic Injectables Market- By Container Market Share, 2021 & 2027
- 7.2 Global Generic Injectables Market: Segment Analysis
- 7.3 By Vials - Market Size and Forecast (2017-2027)
- Table 22: Global Generic Injectables Market- By Vials, By Value (USD Billion), 2017-2027
- 7.4 By Ampoules - Market Size and Forecast (2017-2027)
- Table 23: Global Generic Injectables Market- By Ampoules, By Value (USD Billion), 2017-2027
- 7.5 By Pre-filled Syringes - Market Size and Forecast (2017-2027)
- Table 24: Global Generic Injectables Market- By Pre-filled Syringes, By Value (USD Billion), 2017-2027
- 7.6 By Others - Market Size and Forecast (2017-2027)
- Table 25: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
- 8. Global Generic Injectables Market: Regional Analysis
- 8.1 Competitive Scenario of Global Generic Injectables Market: By Region (2021 & 2027)
- Table 26: Global Generic Injectables Market- By Region Market Share, 2021 & 2027
- 9. North America Generic Injectables Market: An Analysis (2017-2027)
- 9.1 North America Generic Injectables Market: Size and Forecast (2017-2027), By Value
- Table 27: North America Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 28: Prevalence of Cardiovascular Diseases in North America, (in million), 2015-2019
- Table 29: Cancer prevalence in North America (in million), 2020
- Table 30: Prevalence of Multiple Sclerosis in North America, (in 1000ís), 2015-2019
- Table 31: North America Diabetes Prevalence, By Country, 2020 (% of Population Aged 20-79)
- Table 32: North America Diabetes-related health expenditure per person, USD (2021)
- Table 33: North America Current health expenditure per capita (current USD), 2014-18
- Table 34: North America Population ages 65 and above (% of Total Population), 2016-20
- 9.2 North America Generic Injectables Market - Prominent Companies
- 9.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
- Table 35: North America Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- 9.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
- Table 36: North America Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- 9.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
- Table 37: North America Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 9.6 North America Generic Injectables Market: Country Analysis
- 9.7 Market Opportunity Chart of North America Generic Injectables Market - By Country, By Value (Year-2026)
- Table 38: Market Opportunity Chart of North America Generic Injectables Market- By Country, By Value (Year-2027)
- 9.8 Competitive Scenario of North America- By Country
- Table 39: North America Generic Injectables Market- By Country Market Share, 2021 & 2027
- 9.9 United States Generic Injectables Market: Size and Forecast (2017-2027), By Value
- Table 40: United States Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 41: Prevalence of Cardiovascular Diseases in United States, (in million), 2015-2019
- Table 42: Prevalence of Multiple Sclerosis in United States, (in 1000ís), 2016-2019
- Table 43: Cancer prevalence in United States (in million), Year 2020
- Table 44: United States Current health expenditure per capita (current USD), 2016-2020
- Table 45: United States Population aged 65 and above (% of total Population), 2016-20
- Table 46: Estimated people with diabetes in United States (in millions), 2021-2045
- 9.10 United States Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 47: United States Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 48: United States Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 49: United States Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 9.11 Canada Generic Injectables Market: Size and Forecast (2017-2027), By Value
- Table 50: Canada Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 51: Prevalence of Cardiovascular Diseases in Canada, (in million), 2015-2019
- Table 52: Estimated number of Cancer Prevalent cases in Canada, 2020
- Table 53: Prevalence of Multiple sclerosis in Canada, (in 1000ís), 2016-2019
- Table 54: Canada Current health expenditure per capita (current USD), 2017-2021
- Table 55: Canada Population aged 65 and above (% of total Population), 2016-20
- Table 56: Estimated people with diabetes in Canada (in millions), 2021-2045
- 9.12 Canada Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 57: Canada Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 58: Canada Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 59: Canada Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 10. Europe Generic Injectables Market: An Analysis (2017-2027)
- 10.1 Europe Generic Injectables Market by value: Size and Forecast (2017-2027)
- Table 60: Europe Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 61: Europe Prevalence of Cardiovascular Diseases (in Million), 2015-2019
- Table 62: Prevalence of Osteoarthritis Diseases in Europe, (in Million), 2015-2019
- Table 63: Europe estimated number of Cancer prevalence (all ages, in Million), Year 2020
- Table 64: Europe Prevalence of Multiple Sclerosis, 2016-2019 (In 1000ís)
- Table 65: Europe Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
- Table 66: Europe Current health expenditure per capita (current USD), 2015-18
- Table 67: Total expenditure on health per capita in European countries (in USD PPP), 2019
- Table 68: Population ages 65 and above (% of total Population) in European Countries, 2020
- 10.2 Europe Generic Injectables Market: Prominent Companies
- 10.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
- Table 69: Europe Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- 10.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
- Table 70: Europe Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- 10.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
- Table 71: Europe Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 10.6 Europe Generic Injectables Market: Country Analysis
- 10.7 Market Opportunity Chart of Europe Generic Injectables Market - By Country, By Value (Year-2026)
- Table 72: Market Opportunity Chart of Europe Generic Injectables Market- By Country, By Value (Year-2026)
- 10.8 Competitive Scenario of Europe Generic Injectables Market - By Country (2021 & 2027)
- Table 73: Europe Generic Injectables Market- By Country Market Share, 2021 & 2027
- 10.9 Germany Generic Injectables Market: Size and Forecast (2017-2027)
- Table 74: Germany Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 75: Prevalence of Cardiovascular Diseases in Germany, (in million), 2015-2019
- Table 76: Estimated people with diabetes in Germany (in millions), 2021-2045
- Table 77: Prevalence of Multiple Sclerosis in Germany, (in 1000ís), 2016-2019
- Table 78: Germany Current health expenditure per capita (current USD), 2015-2019
- Table 79: Germany Population aged 65 and above (% of total Population), 2016-20
- Table 80: Germany, Estimated percentage of prevalent Cancer cases, 2020
- 10.10 Germany Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 81: Germany Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 82: Germany Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 83: Germany Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 10.11 United Kingdom Generic Injectables Market: Size and Forecast (2017-2027)
- Table 84: United Kingdom Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 85: Estimated people with diabetes in United Kingdom (in millions), 2021-2045
- Table 86: United Kingdom, Estimated percentage of prevalent Cancer cases, 2020
- Table 87: Prevalence of Multiple Sclerosis in United Kingdom, (in 1000ís), 2015-2019
- Table 88: United Kingdom Current health expenditure per capita (current USD), 2015-2019
- Table 89: United Kingdom Population aged 65 and above (% of total Population), 2016-20
- Table 90: Prevalence of Cardiovascular Diseases in United Kingdom, (in million), 2015-2019
- 10.12 United Kingdom Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 91: United Kingdom Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 92: United Kingdom Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 93: United Kingdom Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 10.13 France Generic Injectables Market: Size and Forecast (2017-2027)
- Table 94: France Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 95: Estimated people with diabetes in France (in millions), 2021-2045
- Table 96: France, Estimated percentage of prevalent Cancer cases, 2020
- Table 97: Prevalence of Multiple Sclerosis in France, (in 1000ís), 2015-2019
- Table 98: France Current health expenditure per capita (current USD), 2015-2019
- Table 99: France Population aged 65 and above (% of total Population), 2016-20
- Table 100: Prevalence of Cardiovascular Diseases in France, (in million), 2015-2019
- 10.14 France Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 101: France Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 102: France Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 103: France Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 10.15 Italy Generic Injectables Market: Size and Forecast (2017-2027)
- Table 104: Italy Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 105: Estimated people with diabetes in Italy (in millions), 2021-2045
- Table 106: Italy, Estimated percentage of prevalent Cancer cases, 2020
- Table 107: Prevalence of Multiple Sclerosis in Italy, (in 1000ís), 2015-2019
- Table 108: Italy Current health expenditure per capita (current USD), 2015-2019
- Table 109: Italy Population aged 65 and above (% of total Population), 2016-20
- Table 110: Prevalence of Cardiovascular Diseases in Italy, (in million), 2015-2019
- 10.16 Italy Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 111: Italy Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 112: Italy Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 113: Italy Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 11. Asia Pacific Generic Injectables Market: An Analysis (2017-2027)
- 11.1 Asia Pacific Generic Injectables Market by value: Size and Forecast (2017-2027)
- Table 114: Asia Pacific Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 115: Prevalence of Cardiovascular Diseases in Asia Pacific, (in million), 2015-2019
- Table 116: Cancer prevalence in Asia Pacific (in thousands), Year 2020
- Table 117: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
- Table 118: Asia Pacific Current health expenditure per capita (current USD), 2014-18
- Table 119: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
- Table 120: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
- Table 121: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
- 11.2 Asia Pacific Generic Injectables Market: Prominent Companies
- 11.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
- Table 122: Asia Pacific Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- 11.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
- Table 123: Asia Pacific Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- 11.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
- Table 124: Asia Pacific Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 11.6 Asia Pacific Generic Injectables Market: Country Analysis
- 11.7 Market Opportunity Chart of Asia Pacific Generic Injectables Market - By Country, By Value (Year-2026)
- Table 125: Market Opportunity Chart of Asia Pacific Generic Injectables Market- By Country, By Value (Year-2026)
- 11.8 Competitive Scenario of Asia Pacific Generic Injectables Market - By Country (2021 & 2027)
- Table 126: Asia Pacific Generic Injectables Market- By Country Market Share, 2021 & 2027
- 11.9 China Generic Injectables Market: Size and Forecast (2017-2027)
- Table 127: China Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 128: Estimated people with diabetes in China (in millions), 2021-2045
- Table 129: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
- Table 130: Estimated number of Cancer prevalent cases in China (all ages, in 1000ís), Year 2020
- Table 131: China Current health expenditure per capita (current USD), 2015-2019
- Table 132: China Population aged 65 and above (% of Total Population), 2016-20
- 11.10 China Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 133: China Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 134: China Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 135: China Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 11.11 Japan Generic Injectables Market: Size and Forecast (2017-2027)
- Table 136: Japan Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 137: Estimated people with diabetes in Japan (in millions), 2021-2045
- Table 138: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
- Table 139: Estimated number of Cancer prevalent cases in Japan (all ages, in 1000ís), Year 2020
- Table 140: Japan Healthcare Expenditure Outlook (%)
- Table 141: Japan Population aged 65 and above (% of Total Population), 2016-20
- 11.12 Japan Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 142: Japan Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 143: Japan Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 144: Japan Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 11.13 India Generic Injectables Market: Size and Forecast (2017-2027)
- Table 145: India Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 146: Estimated people with diabetes in India (in millions), 2021-2045
- Table 147: Estimated number of Cancer prevalent cases in India (all ages, in 1000ís), Year 2020
- Table 148: Prevalence of Multiple Sclerosis in India, (in 1000ís), 2016-2019
- Table 149: Estimated value of public health spending in India (from 2017-20, in billions USD)
- Table 150: India Population aged 65 and above (% of Total Population), 2016-20
- Table 151: Prevalence of Cardiovascular Diseases in India, (in million), 2015-2019
- 11.14 India Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 152: India Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 153: India Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 154: India Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 11.15 Australia Generic Injectables Market: Size and Forecast (2017-2027)
- Table 155: Australia Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
- Table 156: Estimated people with diabetes in Australia (in millions), 2021-2045
- Table 157: Estimated number of Cancer prevalent cases in Australia (all ages, in 1000ís), Year 2020
- Table 158: Prevalence of Multiple Sclerosis in Australia, (in 1000ís), 2016-2019
- Table 159: Australia Current health expenditure per capita (current USD), 2015-2019
- Table 160: Australia Population aged 65 and above (% of Total Population), 2016-20
- Table 161: Prevalence of Cardiovascular Diseases in Australia, (in million), 2015-2019
- 11.16 Australia Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
- Table 162: Australia Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
- Table 163: Australia Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
- Table 164: Australia Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
- 12. Global Generic Injectables Market Dynamics
- 12.1 Global Generic Injectables Market Drivers
- 12.2 Global Generic Injectables Market Restraints
- 12.3 Global Generic Injectables Market Trends
- 13. Market Attractiveness and Strategic Analysis
- 13.1 Market Attractiveness Chart of Global Generic Injectables Market - By Molecule Type (Year 2027)
- Table 165: Market Attractiveness Chart of Global Generic Injectables Market- By Molecule Type (Year-2027)
- 13.2 Market Attractiveness Chart of Global Generic Injectables Market - By Therapeutic Area (Year 2027)
- Table 166: Market Attractiveness Chart of Global Generic Injectables Market- By Therapeutic Area (Year-2027)
- 13.3 Market Attractiveness Chart of Global Generic Injectables Market - By Container (Year 2027)
- Table 167: Market Attractiveness Chart of Global Generic Injectables Market- By Container (Year-2027)
- 13.4 Market Attractiveness Chart of Global Generic Injectables Market - By Region (Year 2027)
- Table 168: Market Attractiveness Chart of Global Generic Injectables Market- By Region (Year-2027)
- 14. Competitive Landscape
- 14.1 Market Share of global leading companies
- Table 169: Global Generic Injectables company market share (%), 2021
- 14.2 Market Share of Leading US Companies by Value & by Volume
- Table 170: Market share in generic injectables in US (by value), 2021
- Table 171: Market share in generic injectables in US (by volume), 2021
- 14.3 SWOT Analysis - Global Generic Injectables Market
- 15. Global Generic Injectables Market: List of First-Time Generic Injectables Approvals in 2021
- 16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
- 16.1 Pfizer Inc.
- Table 172: Pfizer Inc. Annual Sales Revenue, 2016-2020 (USD Million)
- Table 173: Pfizer Inc. Net Income, 2016-2020 (USD Million)
- Table 174: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
- 16.2 Novartis
- Table 175: Novartis Annual Sales Revenue (USD Million), 2016-2020
- Table 176: Novartis Annual Net Income/Loss (USD Million), 2016-2020
- Table 177: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
- Table 178: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
- 16.3 Sanofi
- Table 179: Sanofi Sales Revenues, 2016-2020 (USD Million)
- Table 180: Sanofi Gross Profit, 2016-2020 (USD Million)
- Table 181: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
- Table 182: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
- 16.4 Baxter International
- Table 183: Baxter International Sales Revenues, 2016-2020 (USD Million)
- Table 184: Baxter International Net Income, 2016-2020 (USD Million)
- Table 185: Baxter International Sales Revenue Split, By Business Segment (%), FY2020
- Table 186: Baxter International Sales Revenue Split, By Geography Segment (%), FY2020
- 16.5 Fresenius SE & Co KGaA
- Table 187: Fresenius SE & Co KGaA Sales Revenues, 2016-2020 (USD Million)
- Table 188: Fresenius SE & Co KGaA Net Income, 2016-2020 (USD Million)
- Table 189: Fresenius SE & Co KGaA Sales Revenue Split, By Business Segment (%), FY2020
- Table 190: Fresenius SE & Co KGaA Sales Revenue Split, By Geography Segment (%), FY2020
- 16.6 Amneal Pharmaceuticals
- Table 191: Amneal Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
- Table 192: Amneal Pharmaceuticals Net Income, 2016-2020 (USD Million)
- Table 193: Amneal Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
- Table 194: Amneal Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
- 16.7 Hikma Pharmaceuticals
- Table 195: Hikma Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
- Table 196: Hikma Pharmaceuticals Net Income, 20016-2020 (USD Million)
- Table 197: Hikma Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
- Table 198: Hikma Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
- 16.8 Gland Pharma
- Table 199: Gland Pharma Annual Sales Revenue (USD Million), 2017-2020
- Table 200: Gland Pharma Net Income (USD Million), 2017-2020
- Table 201: Gland Pharma Sales Revenue, By Business Segment (%), FY2020
- Table 202: Gland Pharma Sales Revenue, By Geographical Segment (%), FY2020
- 16.9 Teva Pharmaceuticals
- Table 203: Teva Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
- Table 204: Teva Pharmaceuticals Net Income, 2016-2020 (USD Million)
- Table 205: Teva Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
- Table 206: Teva Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
- 16.10 Nichi-iko Pharmaceutical
- Table 207: Nichi-iko Pharmaceutical Sales Revenues, 2016-2020 (USD Million)
- Table 208: Nichi-iko Pharmaceutical Net Income, 2016-2020 (USD Million)
- Table 209: Nichi-iko Pharmaceutical Sales Revenue Split, By Business Segment (%), FY2020
- Table 210: Nichi-iko Pharmaceutical Sales Revenue Split, By Geography Segment (%), FY2020
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.